

Amendments to the Claims

1. (currently amended) A fast dissolving tablet for oral administration which comprises:
 - a therapeutically effective amount of one or more drugs that act as a cyclooxygenase-2 (COX-2) inhibitor;
 - croscarmellose sodium; ~~and~~
 - one or more pharmaceutically acceptable excipients, wherein at least one of the pharmaceutically acceptable excipients comprises a filler; and
 - wherein the fast dissolving tablet dissolves in the mouth.
2. (previously amended) The tablet according to claim 1 wherein the one or more drugs comprise a COX-2 inhibitor.
3. (canceled)
4. (previously amended) The tablet according to claim 1 or 2 wherein the one or more drugs comprise a specific or preferential COX-2 inhibitor.
5. (original) The tablet according to claim 4 wherein the COX-2 inhibitor is selected from the group consisting of meloxicam, rofecoxib, celecoxib, valdecoxib, parecoxib, nabumetone, nimesulide and etodolac.
6. (previously amended) The tablet according to claim 1 wherein the filler is selected from the group consisting of alkali earth metal salts, carbohydrates, celluloses, starches, clays and polyethylene glycols, and mixtures thereof.
7. (previously amended) The tablet according to claim 1 wherein the filler is selected from the group consisting of directly compressible dicalcium phosphate dihydrate, tricalcium phosphate, calcium sulfate, calcium carbonate, calcium hydroxide, aluminium hydroxide, magnesium silicate, aluminium magnesium hydroxide, maltose, maltitol, sorbitol, mannitol, glucose, sucrose, xylitol, lactose, lactose monohydrate, erythritol, fructose, maltodextrins, microcrystalline cellulose, calcium

carboxy methyl cellulose, pregelatinized starch, potato starch, maize starch, kaolin, polyethylene glycol 4000, and mixtures thereof.

8. (previously amended) The tablet according to claim 1 wherein the one or more pharmaceutically acceptable excipients comprises one or more of binders, disintegrants, lubricants, glidants, colouring agents, flavouring agents and sweeteners.

9. (previously amended) The tablet according to claim 8 wherein the binders is selected from the group consisting of microcrystalline cellulose, mannitol, microcrystalline dextrose, directly compressible dicalcium phosphate, amylose and polyvinylpyrrolidone.

10. (original) The tablet according to claim 8 wherein the disintegrant is selected from the group consisting of starches or modified starches, clays, celluloses, algin, cross-linked celluloses, gums, cross-linked polymers, effervescent agents, and mixtures thereof.

11. (original) The tablet according to claim 10 wherein the disintegrant is selected from the group consisting of sodium starch glycolate, corn starch, potato starch, pregelatinized starch, bentonite, montmorillonite, veegum, microcrystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium alginate, alginic acid, croscarmellose sodium, guar gum, xanthan gum, crospovidone; sodium bicarbonate and citric acid, and mixtures thereof.

12. (previously amended) The tablet according to claim 8 wherein the lubricant is selected from the group consisting of talc, magnesium stearate, calcium stearate, stearic acid, magnesium lauryl sulphate and hydrogenated vegetable oil, sodium benzoate, sodium acetate, sodium chloride, leucine, sodium stearyl fumarate, PEG 4000, and mixtures thereof.

13. (previously amended) The tablet according to claim 8 wherein the glidant is selected from the group consisting of colloidal silicon dioxide and talc.

14. (previously amended) The tablet according to claim 8 wherein the colouring agent is selected from any pharmaceutically acceptable colorant.
15. (previously amended) The tablet according to claim 8 wherein the flavouring agent is selected from the group consisting of natural and artificial flavours, mints and essential oils and mixtures thereof.
16. (previously amended) The tablet according to claim 15 wherein the flavouring agent is selected from the group consisting of peppermint, menthol, artificial vanilla, cinnamon, various fruit flavours, both individual and mixed, thymol, eucalyptol and methyl salicylate and mixtures thereof.
17. (previously amended) The tablet according to the claim 8 wherein the sweetener is selected from the group consisting of natural and artificial sweeteners.
18. (previously amended) The tablet according to the claim 17 wherein the sweetener is selected from the group consisting of monosaccharides, disaccharides, polysaccharides, partially hydrolyzed starch, corn syrup solids, sugar alcohols, water-soluble artificial sweeteners, and mixtures thereof.
19. (original) The tablet according to the claim 18 wherein the sweetener may be selected from the group consisting of xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, maltose, sorbitol, xylitol, mannitol, soluble saccharin salts, cyclamate salts, acesulfam-K and free acid form of saccharin and dipeptide based sweeteners, and mixtures thereof.
20. (currently amended) An orally administered, fast dissolving tablet comprising a COX-2 inhibitor, croscarmellose sodium, mannitol, aspartame, colloidal silicon dioxide, magnesium stearate and one or more flavouring agents, and wherein the fast dissolving tablet dissolves in the mouth
21. (withdrawn) A process for preparing a fast dissolving tablet according to claim 2 comprising the steps of:

(a) blending a therapeutically effective amount of COX-2 inhibitor, a filler, and optionally, other pharmaceutical excipients;

(b) compressing the homogeneous mixture obtained in step (a).

22. (withdrawn) The process according to claim 21 wherein the blend is granulated before compression.

23. (withdrawn) The process according to claim 22 wherein the granulation is done by wet or dry granulation methods.

24. (withdrawn) The process according to claim 23 wherein the dry granulation is done by slugging or roller compaction.

25. (previously presented) The tablet according to claim 1 wherein the one or more drugs that act as a cyclooxygenase-2 (COX-2) inhibitor comprises about 1% to about 90% w/w of the tablet.

26. (previously presented) The tablet according to claim 8 wherein the binder comprises about 1% to about 10% w/w of the tablet.

27. (previously presented) The tablet according to claim 8 wherein the lubricant comprises about 0.25% to about 4% w/w of the tablet.

28. (previously presented) The tablet according to claim 8 wherein the glidant comprises about 0.1% to about 10% w/w of the tablet.

29. (previously presented) The tablet according to claim 1 wherein the tablet is prepared by direct compression.

30. (previously presented) The tablet according to claim 5 wherein the tablet comprises between about 2.5 mg and about 100 mg of rofecoxib per tablet.

31. (canceled)